DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $32.00. Thomas Shrader’s rating is based on Denali ...

The releases of the hostages and around 200 prisoners were the second exchange as part of the cease-fire deal in Gaza. Israel said the four hostages, all women, were back in the country. President ...

Jan. 10, 2025 — More than half of 23-year-olds in a European study show restrictive, emotional or uncontrolled eating behaviors, according to new research. ... Climate Fee on Food Could ...

The Walt Disney Company operates as an entertainment company worldwide. It operates through three segments: Entertainment, Sports, and Experiences. The company produces and distributes film and ...

Jan. 24, 2025 — We're nearly one month into 2025, but if you're struggling to hold onto your New Year's resolution, stay strong, as new research shows that forming a healthy habit can take ...